Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

  • There is currently no data for NSCI

Wanda Forms Scientific Advisory Board

16 Mar 2016 07:00

RNS Number : 2148S
NetScientific PLC
16 March 2016
 

 

 

 ("NetScientific" or the "Group")

 

 

Wanda Forms Scientific Advisory Board to Provide Strategic Guidance

London, UK - 16 March 2016 - NetScientific plc (AIM: NSCI), the transatlantic biomedical and healthcare technology group, notes its Digital Health Portfolio company, Wanda, has announced the formation of a Scientific Advisory Board to provide thought leadership and strategic guidance to the Wanda management team. Board members include distinguished physicians, health economics scientists, and technologists committed to advancing clinical outcomes for individuals with chronic disease.

Commenting on the news, NetScientific's Chief Executive Officer, Francois R. Martelet said: "Wanda's technology has broad potential to simplify and improve the lives of people confronted with chronic conditions and, in the near term, to help patients with Congestive Heart Failure and their physicians to monitor risk and predict and prevent readmission to hospital. The calibre of the new SAB members is testament to the quality of the Wanda platform and we look forward to their input as Wanda develops into a world-leading digital health business."

The full text of the announcement issued by Wanda on 15 March 2016 can be found below:

 

Wanda Forms Scientific Advisory Board to Provide Strategic Guidance

 

Inaugural Members include clinical and technology experts committed to advancing the management of chronic disease

 

SAN FRANCISCO - March 15, 2016 Wanda today announced the formation of a Scientific Advisory Board to provide thought leadership and strategic guidance to the Wanda management team. Board members include distinguished physicians, health economics scientists, and technologists committed to advancing clinical outcomes for individuals with chronic disease.

 

"The inaugural members of Wanda's Scientific Advisory Board include an impressive mix of visionaries and opinion leaders across a variety of disciplines," said Wanda CCO Mark Heinemeyer. "All are passionate about advancing state-of-the-art chronic disease management."

 

"This group shares Wanda's belief in the power of excellent design to improve connections with patients, to engage loved ones, and to enhance outcomes," added Wanda CTO Foad Dabiri. "We look forward to working with these industry leaders as we continue to accelerate the development and implementation of the Wanda platform."

 

Wanda's new Scientific Advisory Board members include:

 

Constanzo DiPerna, MD, MBA - Dr. DiPerna is Medical Director of Dignity Health Cancer Institute of Greater Sacramento; Chief of Thoracic Surgery and Medical Director of Chest Disease for Mercy San Juan Medical Center; and Chief of Thoracic Surgery for Dignity Health Mercy Medical Group Sacramento. Dr. DiPerna is also the founder of ONCOVERSE LLC Global Center Network.

 

Clyde E. Wesp, Jr, MD, MAOM - Dr. West is Executive Clinical Strategist at Jacobus Consulting, where he is dedicated to improving the quality and safety of care along the continuum through clinical decision support, evidence-based medicine, and strategic transformation of clinical processes. He is currently a USC Adjunct Professor at the Sol Price School of Public Policy where he teaches Masters students in the area of population health and related clinical issues.

 

Janki Shah, MD - Dr. Shah is the founder and director of the UCLA Northwest Valley Women's Heart Health Program, which strives to ensure that women embrace cardiac screening and early detection of cardiovascular disease, as well as to provide a unique female focus on the education, prevention, early detection, treatment, and management of heart disease. Dr. Shah serves of the Board of Directors of the American Heart Association - Greater Los Angeles.

 

Jeff Moreland, BSN - Moreland is CEO and Chief Patient Officer for Patient Engagement Advisors (PEA). He created PEA as a self-funded effort, driven from the results of a Cleveland Clinic research project that considered the impact of care process gaps created when patients are transitioned across the healthcare continuum. Inc. Magazine has recognized PEA as one of the fastest growing companies in America and The American Business Awards has acknowledged PEA for its patient-focused technology innovation.

 

"Wanda is taking an innovative, science-based approach to solving some of healthcare's toughest and most longstanding problems," said Dr. Shah. "I am honored to serve on Wanda's Scientific Advisory Board and help the company improve the management of chronic disease."

 

Wanda's digital health platform connects the consumer and the clinical care team in a virtual network, intelligently collects critical vital and symptom information, and applies proven machine learning analytics to deliver ongoing risk analysis and decision support. Individuals are equipped to take better care of themselves and clinicians are able to more efficiently engage with those consumers when they need the most assistance maintaining a high quality of life at home.

 

The Wanda solution includes the unique easy-to-use Wanda app running on a smart phone or tablet. The app regularly interacts with an individual to simultaneously capture symptom information and to detect important vital sign measurements. Collected data is securely stored and analyzed on Wanda's cloud-based analytics platform, which utilizes machine learning to help individuals manage their health issues. Should intervention by a healthcare professional be required, Wanda identifies the appropriate provider to guide an appropriate intervention, avoiding potential deterioration of the individual's health condition that could result in disruptive and costly hospitalization.

 

# # #

 

About Wanda

 

San Francisco-based Wanda is dedicated to advancing the effectiveness and efficiency of medicine by using machine learning in place of conventional technologies and by enabling clinicians to make more informed care decisions. Wanda recognizes that remote monitoring and algorithms cannot save lives or reduce hospitalizations unless the individual and their caregivers are promptly informed and highly engaged. Through the collaboration of data science and applied medical research, Wanda has proven that its inline analytics predict preventable events much better than conventional methods. Wanda serves as a diligent companion, providing encouragement and intelligent visual guidance that simplifies and improves lives, while simultaneously helping organizations reduce their care delivery costs. Wanda is a NetScientific portfolio company. More information about Wanda can be found HERE.

 

About NetScientific

NetScientific is a biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people's lives and society through improved diagnosis, prognosis and treatment.

 

For more information, please visit the website at www.netscientific.net

 

 

- Ends -

 

Contact Details

NetScientific

François R. Martelet, M.D., CEO

Mark Nanovich, Interim CFO

 

Tel: +44 (0)20 3514 1800

 

Investec (NOMAD and broker)

Gary Clarence / Daniel Adams

Tel: +44 (0)20 7597 4000

 

Consilium Strategic Communications

Mary-Jane Elliott / Chris Gardner / Jessica Hodgson / Chris Welsh / Laura Thornton

 

Tel: +44 (0)20 3709 5700

Email: netscientific@consilium-comms.com

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRALFFIFVFIELIR
Date   Source Headline
18th Jul 20187:00 amRNSWanda Technology Enhancements
26th Jun 20184:24 pmRNSGrant of Options to Directors
21st Jun 20181:33 pmRNSResult of AGM
6th Jun 20187:00 amRNSBob Englert Appointed CEO of Vortex Biosciences
4th Jun 20187:00 amRNSProAxsis Wins Innovative Business of Year in NI
1st Jun 20187:00 amRNSProAxsis Awarded Invest NI Grant
22nd May 20184:21 pmRNSNotice of AGM and Annual Report & Accounts
21st May 20187:00 amRNSWanda Announces Significant Data with Partner HRS
2nd May 20187:00 amRNSProAxsis to Present New Data at ATS 2018
18th Apr 20185:08 pmRNSDirectors Dealing Notification
16th Apr 20182:04 pmRNSResult of General Meeting
16th Apr 20187:25 amRNSVortex to Present 2 Posters at AACR
11th Apr 201811:39 amRNSResult of Placing
3rd Apr 20184:09 pmRNSPosting of Circular
29th Mar 20187:00 amRNSProposed Placing and Subscription
29th Mar 20187:00 amRNSFull Year Results
19th Mar 20187:00 amRNSWanda Expanding to Orthopedic Analytics
13th Mar 20187:00 amRNSVortex Announces Partnership with BioView
15th Feb 20187:00 amRNSProAxsis Reports First NEATstik Sale
9th Feb 20187:00 amRNSVortex Releases Publication in Nature Scientific
16th Jan 20187:00 amRNSNetScientific Portfolio Update
8th Jan 20187:00 amRNSProAxsis Achieves CE Mark for Plasmin Immunoassay
4th Jan 20187:00 amRNSGlycotestT Completes Diagnostic Evaluation
12th Dec 20177:00 amRNSWanda Awarded Two Patents
21st Nov 20177:00 amRNSProAxsis: Sales Update
7th Nov 20177:00 amRNSVortex Announces First Commercial VTX-1 Sale
2nd Nov 20177:00 amRNSGlycotest Adds Allowed Chinese Patent to Portfolio
1st Nov 201711:00 amRNSVortex Announces Liquid Biopsy Study in NPJ
30th Oct 20177:00 amRNSProAxsis Showcases ProteaseTag® Research at NACFC
27th Oct 20177:00 amRNSProAxsis Partnership - US National Jewish Health
25th Oct 20177:00 amRNSDirectorate Change
5th Oct 20177:00 amRNSGlycotest Granted Japanese Patent
2nd Oct 20177:00 amRNSWanda Awarded US Patent
28th Sep 20177:00 amRNS2017 Interim Results
14th Sep 20177:00 amRNSProAxsis appoints Diagenics Limited as Distributor
11th Sep 20177:00 amRNSProAxsis Signs Partnership: Biotechnology Company
7th Sep 20177:00 amRNSNotice of Interim Results
4th Sep 20177:00 amRNSProAxsis is awarded a European CE Mark
24th Jul 20177:00 amRNSProAxsis awarded a Significant Innovate UK Grant
10th Jul 201712:00 pmRNSPDS Announces Clinical Collaboration with Merck
7th Jul 20177:00 amRNSGlycotest Strengthens Intellectual Property Reach
26th Jun 20177:00 amRNSGlycotest Update
21st Jun 201712:00 pmRNSResult of AGM
16th Jun 201710:05 amRNSHoldings in Company
15th Jun 20172:52 pmRNSHoldings in Company
12th Jun 201712:02 pmRNSResults of General Meeting
12th Jun 201711:10 amRNSResult of Placing
26th May 20173:52 pmRNSNotice of AGM and Annual Report & Accounts
26th May 201712:49 pmRNSResults of Placing and Subscription
25th May 201711:51 amRNSProposed Placing and Subscription

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.